mcm-5 Antibody

2.1. Role in Cancer Biology

• Overexpression in Tumors: MCM5 is upregulated in lung adenocarcinoma (LUAD), oral squamous cell carcinoma (OSCC), and glioblastoma (GBM), correlating with poor prognosis .

  • In LUAD, MCM5 interacts with histone deacetylase 1 (HDAC1), promoting metastasis and reducing patient survival .

  • OSCC studies show MCM5 knockdown reduces cell proliferation by inducing G2/M phase arrest and downregulating cyclin E/CDK2 .

• Therapeutic Target: High MCM5 expression in GBM enhances chemoresistance to temozolomide (TMZ), suggesting its utility as a therapeutic target .

Table 1: MCM5 Expression in Cancer Types

2.2. Viral Replication Mechanisms

• HIV-1 Interaction: MCM5 incorporates into HIV-1 virions and modulates reverse transcription. Both depletion and overexpression of MCM5 impair viral replication, indicating a biphasic role .

2.3. Transcriptional Regulation

• Stat1-Mediated Signaling: MCM5 binds to IFN-γ-activated Stat1 target promoters (e.g., IRF-1) to facilitate transcription, independent of its DNA replication role .

Clinical and Diagnostic Relevance

• Biomarker Potential:

  • MCM5 urine assays are validated for detecting high-risk non-muscle-invasive bladder cancer recurrence .

  • In laryngeal squamous cell carcinoma (LSCC), MCM5 expression correlates with Ki-67, a standard proliferation marker .

Table 2: Clinical Utility of MCM5

Antibody Performance and Validation

• Proteintech (11703-1-AP): Validated in WB, IHC, and IP using lung cancer cell lines and patient tissues .

• Abcam (ab75975): Recombinant monoclonal antibody with specificity confirmed via intracellular flow cytometry and immunofluorescence .